HemoShear Therapeutics: Funding, Investors & Team (Sep 2026)
HemoShear Therapeutics is a biotech firm that specializes in identifying new targets in biology and developing medications for rare metabolic disorders in children. Our ultimate mission is to find drugs that can rescue the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for survival. Our unique technology allows us to replicate diseases by using liver tissue from children with genetic defects, study the disrupted biochemical processes, explore various drug strategies, and select drug candidates that have a high likelihood of succeeding in clinical trials. HemoShear distinguishes itself from other biotech companies through our exclusive models of human diseases and our capacity to recreate and understand intricate human biology. We strongly believe that no other company can rival our expertise in comprehending human hepatic, tumor, or vascular disease biology, and translating those insights into the development of safe and efficient drug treatments. Our commitment lies in comprehending disease biology and striving to discover effective drug treatments that enhance health outcomes and save lives. For further information, please visit www.hemoshear.com.
HemoShear Therapeutics has raised $43.5M across 2 funding rounds on record, the most recent an undisclosed round of $3.5M announced in Nov 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
HemoShear Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2023.
HemoShear Therapeutics Funding Rounds
HemoShear Therapeutics raised $40.0M in a Series A announced in Feb 2021.
2.8 years later, an undisclosed round of $3.5M was announced in Nov 2023.
HemoShear Therapeutics Founders and Leadership Team
Contact details for the HemoShear Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →HemoShear Therapeutics Funding Compared to Other Biotechnology Startups
HemoShear Therapeutics' latest round of $3.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like HemoShear Therapeutics in Biotechnology and Charlottesville
Companies Similar to HemoShear Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
HemoShear Therapeutics Funding FAQs
What does HemoShear Therapeutics do?
HemoShear Therapeutics is a biotech firm that specializes in identifying new targets in biology and developing medications for rare metabolic disorders in children. Our ultimate mission is to find drugs that can rescue the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for survival. Our unique technology allows us to replicate diseases by using liver tissue from children with genetic defects, study the disrupted biochemical processes, explore various drug strategies, and select drug candidates that have a high likelihood of succeeding in clinical trials. HemoShear distinguishes itself from other biotech companies through our exclusive models of human diseases and our capacity to recreate and understand intricate human biology. We strongly believe that no other company can rival our expertise in comprehending human hepatic, tumor, or vascular disease biology, and translating those insights into the development of safe and efficient drug treatments. Our commitment lies in comprehending disease biology and striving to discover effective drug treatments that enhance health outcomes and save lives. For further information, please visit www.hemoshear.com.
How much funding has HemoShear Therapeutics raised?
HemoShear Therapeutics has raised $43.5M across 2 rounds on record. The most recent is an undisclosed round of $3.5M announced in Nov 2023.
When did HemoShear Therapeutics last raise funding?
HemoShear Therapeutics' most recent funding round on record is an undisclosed round of $3.5M, announced in Nov 2023.
Who is the CEO of HemoShear Therapeutics?
Brian R Wamhoff is listed as CEO at HemoShear Therapeutics.
Where is HemoShear Therapeutics headquartered?
HemoShear Therapeutics is based in Charlottesville, Virginia, United States.
How many employees does HemoShear Therapeutics have?
HemoShear Therapeutics is in the 11-50 employee band.
How does HemoShear Therapeutics' funding compare to other Biotechnology startups?
HemoShear Therapeutics' latest round of $3.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's HemoShear Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for HemoShear Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.